Resistance to visceral leishmaniasis is severely compromised in mice deficient of bradykinin B2-receptors

Parasites and Vectors

Volumn 5, Issue 1, 2012, Pages

  Nico, Dirlei ^a   Feijá, Daniel Ferreira ^a   Maran, Naiara ^a   Morrot, Alexandre ^a   Scharfstein, Julio ^a   Palatnik, Marcos ^a   Palatnik De Sousa, Clarisa Beatriz ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

B2 kinin receptor; Leishmania (L.) chagasi; Leishmania (L.) donovani; Resistance; Susceptibility; Visceral leishmaniasis

Indexed keywords

BRADYKININ B2 RECEPTOR; GAMMA INTERFERON; IMMUNOGLOBULIN G2B; PARASITE ANTIGEN;

ADAPTIVE IMMUNITY; AMASTIGOTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DELAYED HYPERSENSITIVITY; FEMALE; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION RESISTANCE; LEISHMANIA CHAGASI; LIVER WEIGHT; MOUSE; NONHUMAN; PARASITE IMMUNITY; PARASITE LOAD; RECEPTOR UPREGULATION; SPLEEN CELL; SPLEEN WEIGHT; VISCERAL LEISHMANIASIS; WILD TYPE;

ANIMALS; DISEASE RESISTANCE; FEMALE; INTERFERON-GAMMA; LEISHMANIA; LEISHMANIASIS, VISCERAL; LEUKOCYTES, MONONUCLEAR; LIVER; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PARASITE LOAD; RECEPTOR, BRADYKININ B2; SPLEEN;

LEISHMANIA DONOVANI; LEISHMANIA DONOVANI CHAGASI; MUS;

EID: 84868700937     PISSN: None     EISSN: 17563305     Source Type: Journal    
DOI: 10.1186/1756-3305-5-261     Document Type: Article

References (41)

1. World Health Organization, Leishmaniasis: background information http://www.who.int/leishmaniasis/en/ ].
2. One Health: the Global Challenge of Epidemic and Endemic Leishmaniasis. Palatnik-de-Sousa CB, Day MJ, Parasites & Vectors 2011 4 197 207
3. Canine leishmaniosis-new concepts and insights on an expanding zoonosis: part one. Baneth G, Koutinas AF, Solano-Gallego L, Bourdeau P, Ferrer L, Trends Parasitol 2008 24 324 330
4. Immunotherapy with the saponin enriched-Leishmune vaccine versus immunochemotherapy in dogs with natural canine visceral leishmaniasis. Borja-Cabrera GP, Santos FN, Santos FB, Trivellato FA, Kawasaki JK, Costa AC, Castro T, Nogueira FS, Moreira MA, Luvizotto MC, Palatnik M, Palatnik-de-Sousa CB, Vaccine 2010 28 597 603
5. Vaccines for leishmaniasis in the fore coming 25 years. Palatnik-de-Sousa CB, Vaccine 2008 26 1709 1724
6. Regulation of Leishmania populations within the host. I. the variable course of Leishmania donovani infections in mice. Bradley DJ, Kirkley J, Clin Exp Immunol 1977 30 119 129 (Pubitemid 8249312)
7. Polymorphism of Slc11a1 (Nramp1) gene and canine leishmaniasis in a case-control study. Sanchez-Robert E, Altet L, Sanchez A, Francino O, J Hered 2005 96 755 758 (Pubitemid 41752432)
8. Genetic and functional evaluation of the role of DLL1 in susceptibility to visceral leishmaniasis in India. Mehrotra S, Fakiola M, Mishra A, Sudarshan M, Tiwary P, Rani DS, Thangaraj K, Rai M, Sundar S, Blackwell JM, Infect Genet Evol 2012 12 1195 1201
9. Divalent cation transport and susceptibility to infectious and autoimmune disease: continuation of the Ity/Lsh/Bcg/Nramp1/Slc11a1 gene story. Blackwell JM, Searle S, Mohamed H, White JK, Immunol Lett 2003 85 197 203 (Pubitemid 36071576)
10. Interleukin 10 gene polymorphisms and development of post kala-azar dermal leishmaniasis in a selected sudanese population. Farouk S, Salih MA, Musa AM, Blackwell JM, Miller EN, Khalil EA, Elhassan AM, Ibrahim ME, Mohamed HS, Public Health Genomics 2010 13 362 367
11. Genetic admixture in Brazilians exposed to infection with Leishmania chagasi. Ettinger NA, Duggal P, Braz RF, Nascimento ET, Beaty TH, Jeronimo SM, Pearson RD, Blackwell JM, Moreno L, Wilson ME, Ann Hum Genet 2009 73 304 313
12. Cutting edge: bradykinin induces IL-12 production by dendritic cells: a danger signal that drives Th1 polarization. Aliberti J, Viola JP, Vieira-de-Abreu A, Bozza PT, Sher A, Scharfstein J, J Immunol 2003 170 5349 5353 (Pubitemid 36617818)
13. Bradykinin B2 Receptors of dendritic cells, acting as sensors of kinins proteolytically released by Trypanosoma cruzi, are critical for the development of protective type-1 responses. Monteiro AC, Schmitz V, Morrot A, de Arruda LB, Nagajyothi F, Granato A, Pesquero JB, Müller-Esterl W, Tanowitz HB, Scharfstein J, PLoS Pathog 2007 3 11 185
14. Cooperative activation of TLR2 and bradykinin B2 receptor is required for induction of type 1 immunity in a mouse model of subcutaneous infection by Trypanosoma cruzi. Monteiro AC, Schmitz V, Svensjo E, Gazzinelli RT, Almeida IC, Todorov A, de Arruda LB, Torrecilhas AC, Pesquero JB, Morrot A, Bouskela E, Bonomo A, Lima AP, Müller-Esterl W, Scharfstein J, J Immunol 2006 177 6325 6335 (Pubitemid 44628851)
15. The kallikrein-kinin system in parasitic infections. Chapter 20. Scharfstein J, Svensjö E, Kinins KG, Berlin/Boston, Bader M, 1 2012 321 330
16. Kinin danger signals proteolytically released by gingipain induce Fimbriae-specific IFN-gamma- and IL-17-producing T cells in mice infected intramucosally with Porphyromonas gingivalis. Monteiro AC, Scovino A, Raposo S, Gaze VM, Cruz C, Svensjö E, Narciso MS, Colombo AP, Pesquero JB, Feres-Filho E, Nguyen KA, Sroka A, Potempa J, Scharfstein J, J Immunol 2009 183 3700 3711
17. Interplay between parasite cysteine proteases and the host kinin system modulates microvascular leakage and macrophage infection by promastigotes of the Leishmania donovani complex. Svensjö E, Batista PR, Brodskyn CI, Silva R, Lima AP, Schmitz V, Saraiva E, Pesquero JB, Mori MA, Müller-Esterl W, Scharfstein J, Microbes Infect 2006 8 206 220 (Pubitemid 43139309)
18. The genetics of susceptibility and resistence in the vertebrate host. Bradley DJ, The Leishmaniaisis, Vol. 2 Academic Press, London, Peters W, Killick Kendrick R, 1 1987 551 581
19. Animal models for infectious diseases caused by parasites: Leishmaniasis. Oliveira CI, Teixiera MJ, Gomes R, Barral A, Brodskyn C, Drug Discov Today 2004 1 81 86 (Pubitemid 41123782)
20. Immunopathogenesis of infection with the visceralizing Leishmania species. Wilson ME, Jeronimo SM, Pearson RD, Microb Pathog 2005 38 147 160 (Pubitemid 40417730)
21. The role of host genetics in leishmaniasis. Sakthianandeswaren A, Foote SJ, Handman E, Trends Parasitol 2009 25 383 391
22. Regulation of Leishmania populations within the host. II. genetic control of acute susceptibility of mice to Leishmania donovani infection. Bradley DJ, Clin Exp Immunol 1977 30 130 140 (Pubitemid 8249313)
23. Defective CCR7 expression on dendritic cells contributes to the development of visceral leishmaniasis. Ato M, Stäger S, Engwerda CR, Kaye PM, Nat Immunol 2002 3 1185 1191 (Pubitemid 35469703)
24. Anti-nociceptive effect of kinin B1 and B2 receptor antagonists on peripheral neuropathy induced by paclitaxel in mice. Costa R, Motta EM, Dutra RC, Manjavachi MN, Bento AF, Malinsky FR, Pesquero JB, Calixto JB, Br J Pharmacol 2011 164 681 693
25. Effects of the bradykinin B1 receptor antagonist des-Arg9[Leu8]bradykinin and genetic disruption of the B2 receptor on nociception in rats and mice. Rupniak NM, Boyce S, Webb JK, Williams AR, Carlson EJ, Hill RG, Borkowski JA, Hess JF, Pain 1997 71 89 97 (Pubitemid 27245235)
26. Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis. Santos WR, de Lima VM, de Souza EP, Bernardo RR, Palatnik M, de Sousa Palatnik CB, Vaccine 2002 21 30 43 (Pubitemid 35355720)
27. Adaptive immunity against Leishmania nucleoside hydrolase maps its C-terminal domain as the target of the CD4+ T cell-driven protective response. Nico D, Claser C, Borja-Cabrera GP, Travassos LR, Palatnik M, Soares IS, Rodrigues MM, Palatnik-de-Sousa CB, PLoS Negl Trop Dis 2010 4 11 866
28. Cytokine Responses to Novel Antigens in a Peri-Urban Population in Brazil Exposed to Leishmania infantum chagasi. Stober CB, Jeronimo SM, Pontes NN, Miller EN, Blackwell JM, AmJTrop Med Hyg 2012 Epub ahead of print
29. Immunodominant antigens of Leishmania chagasi associated with protection against human visceral leishmaniasis. Abánades DR, Arruda LV, Arruda ES, Pinto JR, Palma MS, Aquino D, Caldas AJ, Soto M, Barral A, Barral-Netto M, PLoS Negl Trop Dis 2012 6 1687
30. Vaccines for canine leishmaniasis. Palatnik-de-Sousa CB, Front Immunol 2012 3 69
31. Correlates of protection induced by vaccination. Plotkin SA, Clin Vaccine Immunol 2010 17 1055 1065
32. Immunoglobulin G subclass distribution in canine leishmaniosis: a review and analysis of pitfalls in interpretation. Day MJ, Vet Parasitol 2007 147 2 8 (Pubitemid 46770980)
33. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum. Rafati S, Nakhaee A, Taheri T, Taslimi Y, Darabi H, Eravani D, Sanos S, Kaye P, Taghikhani M, Jamshidi S, Rad MA, Vaccine 2005 23 3716 3725 (Pubitemid 40692418)
34. IgG subclass profile of serum antibodies to Leishmania chagasi in naturally infected and vaccinated dogs. Oliveira TM, Mineo TW, Bason M, Day MJ, Machado RZ, Vet Parasitol 2009 162 16 22
35. Towards multilocus sequence typing of the Leishmania donovani complex: resolving genotypes and haplotypes for five polymorphic metabolic enzymes (ASAT, GPI, NH1, NH2, PGD). Mauricio IL, Yeo M, Baghaei M, Doto D, Pratlong F, Int J Parasitol 2006 36 757 769 (Pubitemid 43866079)
36. Crystal structures of T. vivax nucleoside hydrolase in complex with new potent and specific inhibitors. Versées W, Goeminne A, Berg M, Vandemeulebroucke A, Haemers A, Augustyns K, Steyaert J, Biochim Biophys Acta 2009 1794 953 960
37. Nucleoside hydrolase from Leishmania(L.) donovani is an antigen diagnostic for visceral leishmaniasis. Santana DM, Borja-Cabrera GP, de Paraguai Souza E, Sturm NR, de Palatnik Sousa CB, Campbell DA, Mol Biochem Parasitol 2002 120 315 319 (Pubitemid 34233798)
38. Enhanced hematopoietic activity accompanies parasite expansion in the spleen and bone marrow of mice infected with Leishmania donovani. Cotterell SE, Engwerda CR, Kaye PM, Infect Immun 2000 68 1840 1848 (Pubitemid 30164807)
39. Immunohistological features of visceral leishmaniasis in BALB/c mice. Carrián J, Nieto A, Iborra S, Iniesta V, Soto M, Folgueira C, Abanades DR, Requena JM, Alonso C, Parasite Immunol 2006 28 173 183
40. Balancing immunity and pathology in visceral leishmaniasis. Stanley AC, Engwerda CR, Immunol Cell Biol 2007 85 138 147 (Pubitemid 46398719)
41. The FML-vaccine against canine visceral leishmaniasis: from the second generation to the synthetic vaccine. Palatnik-de-Sousa CB, Barbosa AF, Oliveira SM, Nico D, Bernardo RR, Santos WR, Rodrigues MM, Soares I, Borja Cabrera GP, Exp. Rev Vaccines 2008 7 833 851